Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
I had the opportunity to sit down with Dr. Matthew Horton, a pathologist who works with my own group at Swedish Cancer Institute in Seattle, at a pathology company called CellNetix. He did subspecialty training in lung pathology and is a terrific resource for my colleagues and me, and now for a wider audience.
The first part of our discussion focused on the major subtypes (called histologies) of NSCLC, including adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and the related large cell neuroendocrine carcinomas, along with a significant fraction of NSCLC tumors that can't be classified despite our efforts. So check out the links below for the audio and video versions of our discussion (the video with a few images of what we're talking about), and the associated transcript and figures.
dr-horton-intro-to-lc-path-nsclc-subtypes-audio-podcast
dr-horton-intro-to-lc-path-nsclc-subtypes-transcript
dr-horton-intro-to-lc-path-nsclc-subtypes-figures
In subsequent parts of this discussion, we'll cover the neuroendocrine family that ranges from carcinoids to small cell lung cancer and large cell neuroendocrine carcinomas, the different subtypes of adenocarcinomas, and other aspects of lung cancer pathology.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.